bioAffinity's CyPath Lung Cancer Test Backed By New Flow Cytometry Guidelines
Portfolio Pulse from Benzinga Newsdesk
bioAffinity's CyPath Lung Cancer Test has received support from new flow cytometry guidelines. VP Jennifer Rebeles contributed to an expert panel that published best practices for rare sample testing in a peer-reviewed journal.
October 16, 2024 | 12:11 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
bioAffinity's CyPath Lung Cancer Test is supported by new flow cytometry guidelines, enhancing its credibility and potential market acceptance.
The support from new guidelines enhances the credibility of bioAffinity's CyPath Lung Cancer Test, potentially increasing its acceptance in the market. This is likely to positively impact BIAF's stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90